SEC Form 4 · accession 0001193125-26-359678
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Justin B. Klee
Officer — Co-Chief Executive Officer · Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2026 | A | 60,039 | $0.00 | A | 3,643,520 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.